During her last visit to Latvia, the President of the European Commission Ursula Von Der Leyen, together with the Prime Minister of Latvia Krišjānis Kariņš, made a tour of the Baltic Biomaterials Centre of Excellence, established in 2020 through financial support from the EU’s Framework Programme for Research and Innovation Horizon 2020.
To welcome President Von Der Leyen and Prime Minister Kariņš a team of scientists displayed preparation of calcium phosphate bone cements - new implant materials for bone tissue regeneration that is the core activity of the Centre. The Baltic Biomaterials Centre of Excellence (BBCE CoE) is in fact a Teaming - Phase 2 project aiming at the development of biomaterials for bone regeneration and solutions for creative biomedical applications.
The official visit to Latvia of EC President Von Der Leyen took place in the context of the EU Recovery and Resilience Mechanism, the Next Generation EU initiative and Latvian National Recovery Plan.
About the Baltic Biomaterials Centre of Excellence
The Baltic Biomaterials Centre of Excellenceproject is based on the long-term strategic cooperation between Riga Technical University, Latvian Institute of Organic Synthesis, Rīga Stradiņš University and LLC Rīga Stradiņš University Institute of Stomatology, on the one hand (‘Widening’ partners), and AO Research Institute Davos, Switzerland and Friedrich-Alexander University of Erlangen- Nuremberg, Germany, on the other hand (‘Advanced’ partners).
BBCE CoE aims to bring high performance products into the market through a strong cooperation with core partners in Latvia and industry, including SMEs.
Since the start of the project in January 2020, the Consortium has been very active and able to adapt to emerging restrictions determined by COVID-19 pandemic, carrying out dissemination and engagement with policy makers.
©Valsts kanceleja/ State Chancellery of Latvia - Flickr https://www.flickr.com/photos/valstskanceleja/51263633973/in/album-72157719440904878/
Baltic Biomaterials Centre of Excellence (Grant Agreement 857287) on CORDIS
- 1 juuli 2021